---
title: "Sinotherapeutics Inc. (688247.SH)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/688247.SH.md"
symbol: "688247.SH"
name: "Sinotherapeutics Inc."
industry: "Pharmaceuticals"
datetime: "2026-05-20T14:06:30.910Z"
locales:
  - [en](https://longbridge.com/en/quote/688247.SH.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/688247.SH.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/688247.SH.md)
---

# Sinotherapeutics Inc. (688247.SH)

## Company Overview

Sinotherapeutics Inc., a specialty pharmaceutical company, research, develops, manufactures, and commercializes generic and formulation products in China. The company’s products are indicated for infection, oncology and rheumatology, gastroenterology and metabolism, neurology, cardiology, and nephrology. It offers posaconazole delayed-release tablets; olaparib, exemestane, and tofacitinib extended-release tablets; and mesalamine delayed-release, dapagliflozin and metformin hydrochloride sustained-release, sitagliptin and metformin hydrochloride sustained-release tablets, and ursodeoxycholic ACID Capsules. The company also provides bupropion hydrochloride extended-release tablets, and paroxetine and pregabalin extended-release tablets; propafenone hydrochloride extended-release capsules; and sevelamer carbonate tablets.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.sinotph.com](https://www.sinotph.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:09.000Z

**Overall: C (0.51)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 146 / 215 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -15.11% |  |
| Net Profit YoY | -65.24% |  |
| P/B Ratio | 3.21 |  |
| Dividend Ratio | 0.66% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 4209936741.98 |  |
| Revenue | 432957330.24 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 3.35% | C |
| Profit Margin | 10.08% | B |
| Gross Margin | 38.98% | B |
| Revenue YoY | -15.11% | E |
| Net Profit YoY | -65.24% | E |
| Total Assets YoY | -0.99% | D |
| Net Assets YoY | 1.16% | C |
| Cash Flow Margin | 160.51% | B |
| OCF YoY | -15.11% | E |
| Turnover | 0.30 | D |
| Gearing Ratio | 10.01% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Sinotherapeutics Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-15.11%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-65.24%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "3.21",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.66%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "4209936741.98",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "432957330.24",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "3.35%",
          "rating": "C"
        },
        {
          "name": "Profit Margin",
          "value": "10.08%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "38.98%",
          "rating": "B"
        },
        {
          "name": "Revenue YoY",
          "value": "-15.11%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-65.24%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "-0.99%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "1.16%",
          "rating": "C"
        },
        {
          "name": "Cash Flow Margin",
          "value": "160.51%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "-15.11%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.30",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "10.01%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 94.82 | 137/215 | 47.87 | 44.36 | 40.79 |
| PB | 3.16 | 148/215 | 3.82 | 3.61 | 3.37 |
| PS (TTM) | 9.56 | 183/215 | 10.07 | 9.63 | 9.15 |
| Dividend Yield | 0.67% | 116/215 | 0.65% | 0.60% | 0.56% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Allist (688578.SH) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | A | B | A |
| 03 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 05 | Haisco (002653.SZ) | A | A | B | B | B | B |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/688247.SH/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/688247.SH/norm.md)
- [Related News](https://longbridge.com/en/quote/688247.SH/news.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**